Trial Profile
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Dec 2023
Price :
$35
*
At a glance
- Drugs AL-002 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms INVOKE-2
- Sponsors Alector
- 13 Nov 2023 Planned End Date changed from 11 Nov 2024 to 15 Oct 2024.
- 13 Nov 2023 Planned primary completion date changed from 3 Oct 2024 to 7 Sep 2024.
- 05 Sep 2023 Status changed from recruiting to active, no longer recruiting.